PIN1 and cancer: Thanks to Pin1’s complicated networks with so many pathways in plenty of cancer cells, drug companies such as Pfizer Global R&D [33–35] and Vernalis Ltd [36, 37] as well as several academic laboratories [38–42] have developed some anti-cancer therapy targeting Pin1.